INDOCO REMEDIES LTD. vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of INDOCO REMEDIES LTD. (INDOCO) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

INDOCO logo
INDOCO REMEDIES LTD.
INDOCO
₹243.3-0.02%
VS
TORNTPHARM logo
TORRENT PHARMACEUTICALS L
TORNTPHARM
₹4,954-2.21%
Leads on the numbers
The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads INDOCO vs TORNTPHARM on 11 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability04
  • Growth01
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

TORNTPHARM takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

712.70
P/E ratio
77.50
2.39
P/B ratio
18.67
0.08%
Dividend yield
0.76%
₹0.34
EPS
₹63.92

Profitability

TORNTPHARM takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

-9.42%
Return on equity
27.40%
1.00%
Return on capital
15.00%
8.00%
EBITDA margin
33.00%
-5.37%
Net margin
15.29%

Growth

TORNTPHARM takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

3.40%
Revenue CAGR (3Y)
13.27%
—
Profit CAGR (3Y) even
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2,398 Cr
Market cap
₹1.68L Cr
₹1,845 Cr
Revenue
₹13,980 Cr
₹-99 Cr
Net profit
₹2,138 Cr
0.69
Debt / equity
1.69
INDOCO REMEDIES LTD.
  • + ["Company's working capital requirements have reduced from 40.8 days to 21.3 days"]
  • − ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of 8.25% over past five years.", "Company has a low return on equity of -2.45% over last 3 years.", "Earnings include an other income of Rs.98.3 Cr."]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • − ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
INDOCO REMEDIES LTD. full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.